Recent advances in the biology and treatment of B-cell acute lymphoblastic leukemia

Blood and Lymphatic Cancer : Targets and Therapy
Mehrdad Hefazi, Mark R Litzow

Abstract

Acute lymphoblastic leukemia (ALL) is a hematologic malignancy arising from precursors of the lymphoid lineage. Conventional cytotoxic chemotherapies have resulted in high cure rates of up to 90% in pediatric ALL, but the outcomes for adult patients remain suboptimal with 5-year survival rates of only 30%-40%. Over the last decade, major advances have been made in our understanding and management of ALL. Identification of new prognostic genomic markers and incorporation of minimal residual diseases' assessment into therapeutic protocols have improved risk stratification and treatment strategies. The use of pediatric-inspired regimens for adolescent and young adults, and the advent of tyrosine kinase inhibitors and novel targeted therapies, including monoclonal antibodies and chimeric antigen receptor T cells, have redefined the therapeutic paradigm of ALL, and significantly improved the outcomes. In this article, we will provide an overview of the current knowledge regarding the biology and treatment of ALL, and highlight recent diagnostic and therapeutic advances made in this area over the past 5 years.

Citations

Feb 19, 2021·NPJ Precision Oncology·Kinjal ShahJulhash U Kazi

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry

Clinical Trials Mentioned

NCT01471782
NCT02143414
NCT02003222
NCT03150693

Software Mentioned

EuroFlow

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Related Papers

Critical Reviews in Oncology/hematology
Sujata Narayanan, Paul J Shami
Pediatric Blood & Cancer
Jessica HochbergMitchell S Cairo
[Rinshō ketsueki] The Japanese journal of clinical hematology
Fumihiko Hayakawa
© 2021 Meta ULC. All rights reserved